GSK and Innoviva have published data from a study in which Anoro Ellipta umeclidinium/vilanterol demonstrated superior lung function improvement in COPD patients compared to Stiolto Respimat tiotropium/olodaterol. The data were published in Advances in Therapy and at the 2017 CHEST meeting. The study, which enrolled 236 COPD patients, measured trough FEV1 at 8 … [Read more...] about Study shows Anoro Ellipta superior to Stiolto Respimat for improving lung function in COPD patients
News
Karen Reeves appointed as President and Chief Medical Officer of AZTherapies
AZTherapies, which is developing an inhaled cromolyn/oral ibuprofen combination therapy for the treatment of Alzheimer's disease, has appointed former Pfizer executive Karen Reeves as President and Chief Medical Officer. The company's ALZT-OP1 combination is currently in Phase 3 development. Reeves was most recently VP, Head Global Clinical Submissions Quality and … [Read more...] about Karen Reeves appointed as President and Chief Medical Officer of AZTherapies
Theravance Biopharma opens corporate office in Dublin, Ireland
Theravance Biopharma has opened a corporate office in Dublin, Ireland and plans to hire 30 new employees over the next 2 years, the company said. The company also announced that it and its partner Mylan had presented additional data from 2 Phase 3 trials of TD-4208 inhaled revefenacin at the 2017 CHEST meeting. Topline results from the Phase 3 trials were released … [Read more...] about Theravance Biopharma opens corporate office in Dublin, Ireland
Novoteris announces plans for Phase 2a trial of Thiolanox for NTM lung infections
Novoteris has announced that Health Canada has okayed a planned Phase 2a clinical trial of the company's Thiolanox inhaled nitric oxide gas for the treatment of non-tuberculous mycobacteria (NTM) lung infections. The study will enroll 10 patients excluded from an ongoing Phase 2 trial of Thiolanox in cystic fibrosis patients. In 2015, the company received $2.8 … [Read more...] about Novoteris announces plans for Phase 2a trial of Thiolanox for NTM lung infections
Capsugel adds powder micro-dosing services at its Edinburgh facility
Capsugel has announced the addition of an Xcelodose 600S filling machine for micro-dosing of powders into capsules at its facility in Edinburgh, Scotland. Capsugel was acquired by Lonza earlier this year. The Edinburgh facility's Site Head Jane Fraser said, “We are pleased to add API-in-capsule micro-dosing services to our clinical services offering at our … [Read more...] about Capsugel adds powder micro-dosing services at its Edinburgh facility
Cyrano Therapeutics partners with Shanghai Newsummit on intranasal theophylline for hyposmia
Cyrano Therapeutics has announced a partnership agreement with Chinese CRO Shanghai Newsummit Biopharma (Newsummit) for development of Cyrano's intranasal theophylline for the treatment of taste and smell disorders in China. Newsummit will provide development services to a new Cyrano subsidiary called Wenzhou Cyrano, with the goal of approval by the … [Read more...] about Cyrano Therapeutics partners with Shanghai Newsummit on intranasal theophylline for hyposmia
Impel Neuropharma initiates Phase 1 trial of INP104 intranasal dihydroergotamine
Impel NeuroPharma has announced the initiation of a Phase 1 trial of INP104 intranasal dihydroergotamine (DHE), which the company is developing for the treatment of acute migraine headache. The bioavailability study, which is taking place in Australia, will compare INP104 to an approved intravenous DHE formulation and to Valeant's Migranal DHE nasal spray, the … [Read more...] about Impel Neuropharma initiates Phase 1 trial of INP104 intranasal dihydroergotamine
Optinose announces five appointments
Optinose has announced the appointments of Ricci Whitlow as Vice President of Technical Operations, Harry Sacks as VP of Medical Affairs and Corporate Medical Officer, John Peterkins as VP of Market Access, David Fabbri as VP of Sales, and Andrew Muzsi as VP of Marketing. The company's Xhance fluticasone propionate nasal spray for the treatment of nasal polyps … [Read more...] about Optinose announces five appointments
Savara to develop Molgradex for the treatment of NTM lung infections
Savara has announced that it will develop its Molgradex inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and plans to initiate a Phase 2a trial for that indication in early 2018. The company is also developing Molgradex for the treatment of autoimmune pulmonary alveolar … [Read more...] about Savara to develop Molgradex for the treatment of NTM lung infections
Milestone Pharmaceuticals hires Lorenz Muller as Chief Commercial Officer
Intranasal etripamil developer Milestone Pharmaceuticals has announced the appointment of Lorenz Muller as Chief Commercial Officer. Muller was most recently VP, Marketing at Exact Sciences Corporation and has previously held positions at Daiichi Sankyo, CV Therapeutics , and Merck. In August 2017, Milestone announced that it had raised $55 million for Phase 3 … [Read more...] about Milestone Pharmaceuticals hires Lorenz Muller as Chief Commercial Officer